Ioannis Kournoutas,Brittany L Siontis Ioannis Kournoutas
Liquid biopsies represent a promising and minimally invasive approach to diagnosing and monitoring cancer. In recent years, studies across a multitude of solid organ malignancies have suggested the clinical utility of biomarkers such as cir...
Q23.82024 Review Current treatment options in oncology. 2025 Mar 12. DOI:10.1007/s11864-025-01303-x 2025
Tom Wei-Wu Chen Tom Wei-Wu Chen
Recent clinical trials have investigated immune checkpoint inhibitors (ICIs) alone, in combination with tyrosine kinase inhibitors (TKIs), or with chemotherapy in angiosarcoma, yielding mixed results across subtypes. Single-agent ICI therap...
Q23.82024 Review Current treatment options in oncology. 2025 Mar 8. DOI:10.1007/s11864-025-01307-7 2025
Lijuan He,Ben Liu,Zhuanfang Wang et al. Lijuan He et al.
Gastric cancer (GC) is a deadly disease worldwide, and trastuzumab in combination with chemotherapy has been the standard first-line treatment for HER2-positive GC following the TOGA trial. Besides adjuvant therapy, HER2-directed therapy is...
Q23.82024 Review Current treatment options in oncology. 2025 Mar 8. DOI:10.1007/s11864-025-01300-0 2025
Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies [0.03%]
Demitrios Dedousis,Elyse Gadra,Joseph Van Galen et al. Demitrios Dedousis et al.
Gastrointestinal stromal tumors (GIST) are the most common gastrointestinal soft tissue sarcomas, with an incidence of about 15 cases per million person-years. Approximately 15% of GIST develop due to succinate dehydrogenase deficiency (SDH...
Q23.82024 Review Current treatment options in oncology. 2025 Mar 6. DOI:10.1007/s11864-025-01304-w 2025
Jing Jiao,You Wu,Shaoxian Wu et al. Jing Jiao et al.
Colorectal cancer, ranking as the third most prevalent malignancy globally, substantially benefits from both immunotherapy and VEGF/VEGFR inhibitors. Nevertheless, the use of monotherapy proves inadequate in effectively tackling the heterog...
Q23.82024 Review Current treatment options in oncology. 2025 Mar 6. DOI:10.1007/s11864-025-01306-8 2025
Megan Gorman,Karin Shih Megan Gorman
Symptoms of menopause and the sequelae of gynecologic cancer treatment can be severe in their physical and mental impact on patient quality of life. Survivors of certain gynecologic cancers - namely, early-stage, low-grade endometrial cance...
Q23.82024 Review Current treatment options in oncology. 2025 Mar 5. DOI:10.1007/s11864-025-01298-5 2025
Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma [0.03%]
Fatemeh Karimi,Mojtaba Aghaei,Najmaldin Saki Fatemeh Karimi
Multiple myeloma (MM) is classified as a lymphoproliferative disorder that remains an incurable malignancy despite improved patient survival with new drug therapies. Polymorphisms are essential in determining the effectiveness and outcome o...
Q23.82024 Review Current treatment options in oncology. 2025 Mar 5. DOI:10.1007/s11864-025-01295-8 2025
Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management [0.03%] 紫杉烷相关性急性疼痛综合征的特点及治疗
Yoshitaka Saito Yoshitaka Saito
Taxane-associated acute pain syndrome (T-APS) is one of the most common adverse effects of taxane treatment and significantly reduces the quality of life and activities of daily living of patients. T-APS is recognized as myalgia and arthral...
Q23.82024 Review Current treatment options in oncology. 2025 Feb 28. DOI:10.1007/s11864-025-01302-y 2025
C Tran,H Diaz-Ayllon,D Abulez et al. C Tran et al.
Gynecological cancers, including cervical, endometrial, ovarian, and vulvovaginal cancer, have increasing incidence and mortality globally over the last three decades. In that time, there have been advances in medical therapies and paradigm...
Q23.82024 Review Current treatment options in oncology. 2025 Feb 27. DOI:10.1007/s11864-025-01301-z 2025
Ana Kouri,Janelle P Darby Ana Kouri
There is an increasing use of medical management for gynecologic cancers given the rise in neoadjuvant therapies, delayed childbearing, and use of assisted reproductive technology. Chemotherapy, albeit broadly used in most gynecologic cance...
Q23.82024 Review Current treatment options in oncology. 2025 Feb 19. DOI:10.1007/s11864-025-01299-4 2025